Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough products approved and launched in Japan

This article was originally published in Scrip

Executive Summary

Schering-Ploughhas received formal approval in Japan for its once-daily intranasal steroid Nasonex (mometasone furoate monohydrate), for adult allergic rhinitis. The product will be the first of its type in the country, where the disorder affects 18-23 million people, the company noted. It was recommended in May (Scrip Online, May 29th, 2008) and a launch after price listing is expected in the autumn. Aroglycem (diazoxide) for hyperinsulinism, which received a priority review, has just been launched and is reimbursed at ¥251.80 ($2.36) per 25mg capsule.

Topics

UsernamePublicRestriction

Register

SC004631

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel